Moberg Pharma’s partner launches Kerasal Nail in China
STOCKHOLM, May 19th, 2015. Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, has initiated the launch of Kerasal Nail® in China. TV commercials and other advertising started this week in certain parts of southern China.
Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company - includes Italy, China and eight countries in Southeast Asia. In addition to China, launch activities have previously been initiated in Malaysia, Singapore and Hong Kong. Preparations are ongoing in the other markets in the region.
"We are very pleased with the progress and that the launch of Kerasal Nail now has started in China. Kerasal Nail has significant potential in the region. Assuming successful launches, we expect the region to become an important contributor to revenues and earnings from 2015 and onwards," said Peter Wolpert, CEO of Moberg Pharma AB.
About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. (CET) on May 19, 2015.
For additional information contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 7135, E-mail: email@example.com
Anna Ljung, CFO, Phone: +46 (0)70 - 766 60 30, E-mail: firstname.lastname@example.org
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Jointflex®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further information, please visit: www.mobergpharma.com.